Summary:
PharmaFrontiers is a commercialization driven biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes. The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T-cell vaccination technologies.
Visit PharmaFrontiers.

Description (Web site quote):
PharmaFrontiers is a commercialization driven biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes. The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T-cell vaccination technologies. The company is currently in Phase I/II clinical trials of it's novel therapeutic vaccine TovaxinTM, and is in preclinical development of it's autologous stem cell therapy for the indication of congestive heart failure.
Visit PharmaFrontiers.